Description
Created On: 2020-07-15
Record Count: 4
Primary Industries
- Drugs
- Biotechnology
- Veterinary
- Diagnostic
- Cancer
- Therapeutic
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 28727
GDF-8 Derivative Product shall mean any pharmaceutical product which primarily acts as
(i) an antagonist or agonist of GDF-8 or the GDF-8 receptor,
(ii) a vaccine against GDF-8,
(iii) a modifier of GDF-8 synthesis, or
(iv) a modulator of the GDF-8 signal transduction pathway, only to the extent that such pharmaceutical product is both (a) developed or sold for the purposes of modulating the effects of GDF-8, and (b) is covered by one or more Valid Claims included within the applicable GDF-8 Patent Rights licensed
GDF-8 Product shall mean GDF-8, including any and all
(i) formulations, mixtures or compositions of GDF-8,
(ii) antibodies targeted against GDF-8,
(iii) receptors for which GDF-8 is a ligand,
(iv) antisense molecules or ribozymes that modulate the in vivo production of GDF-8, and
(v) other products for research, diagnostic or therapeutic use containing GDF-8 or any of (i) through (iv) above, which, or which the manufacture use or sale of which, is covered by one or more Valid Claims included within the applicable GDF-8 Patent Rights licensed.
GDF-8 Patent Rights shall mean, with respect to GDF-8, any GDF-8 Product, or any GDF-8 Derivative Product (a) all Patents covering inventions
Our initial focus in the GDF area has been on technologies incorporating Myostatin (also known as GDF-8), a naturally occurring, patented protein that acts to limit skeletal muscle development. Studies have demonstrated that the removal or inhibition of Myostatin results in accelerated and increased development of skeletal muscle tissue (i.e., meat). We have an early stage discovery initiative focused on the identification of agents to effect the inhibition of Myostatin in beef, poultry and swine.
Growth differentiation factor 8, abbreviated GDF-8) is a protein that in humans is encoded by the MSTN gene.
IPSCIO Record ID: 26019
GDF-8 Derivative Product shall mean any pharmaceutical product which primarily acts as
(i) an antagonist or agonist of GDF-8 or the GDF-8 receptor,
(ii) a vaccine against GDF-8,
(iii) a modifier of GDF-8 synthesis, or
(iv) a modulator of the GDF-8 signal transduction pathway, only to the extent that such pharmaceutical product is both (a) developed or sold for the purposes of modulating the effects of GDF-8, and (b) is covered by one or more Valid Claims included within the applicable GDF-8 Patent Rights licensed.
GDF-8 Product shall mean GDF-8, including any and all
(i) formulations, mixtures or compositions of GDF-8,
(ii) antibodies targeted against GDF-8,
(iii) receptors for which GDF-8 is a ligand,
(iv) antisense molecules or ribozymes that modulate the in vivo production of GDF-8, and
(v) other products for research, diagnostic or therapeutic use containing GDF-8 or any of (i) through
(iv) above, which, or which the manufacture use or sale of which, is covered by one or more Valid Claims included within the applicable GDF-8 Patent Rights licensed.
GDF-8 Patent Rights shall mean, with respect to GDF-8, any GDF-8 Product, or any GDF-8 Derivative Product (a) all Patents covering inventions.
Our initial focus in the GDF area has been on technologies incorporating Myostatin (also known as GDF-8), a naturally occurring, patented protein that acts to limit skeletal muscle development. Studies have demonstrated that the removal or inhibition of Myostatin results in accelerated and increased development of skeletal muscle tissue (i.e., meat). We have an early stage discovery initiative focused on the identification of agents to effect the inhibition of Myostatin in beef, poultry and swine.
Growth differentiation factor 8, abbreviated GDF-8) is a protein that in humans is encoded by the MSTN gene.
IPSCIO Record ID: 7498
Licensee may grant sublicenses under this license only to one other party in any country for each indication of a Research, Diagnostic and Veterinary Use at any one time.
'TGF-beta' shall mean any protein which is a member of that class of proteins designated as TGF-beta or transforming growth factor-beta (but excluding TGF-beta 2 or TGF-beta Heterodimer), and/or (i) fragments, fusions or precursors of the foregoing, and/or (ii) any derivative protein which results from making deletions, substitutions and/or additions of one or more amino acids to the structure of a TGF-beta (but excluding TGF-beta 2 or TGF-beta Heterodimer), provided that such derivative protein is more similar in structure to the TGF-beta from which it was derived than it is to TGF-beta 2 or TGF-beta Heterodimer and provided that the primary biological activity of the derivative protein is substantially the same as the primary biological activity of the TGF- beta from which it was derived.
'TGF-beta 2' shall mean a protein comprising the amino acid sequence set forth and/or (i) fragments, fusions or precursors of the foregoing, and/or (ii) any derivative protein which results from making deletions, substitutions or additions of one or more amino acids to the structure.
'TGF-beta Heterodimer' shall mean the TGF-beta 2.3 heterodimer.
'TGF-beta Receptor' shall mean a protein, including a lipoprotein or glycoprotein, that interacts with TGF-beta so as to modulate its activity and that binds TGF-beta with high affinity (Kd 1000nM or less). Such TGF-beta Receptor may be cell associated or in soluble form.
Product' shall mean any pharmaceutical formulation or product or method or system which contains the protein TGF-beta 2, TGF-beta Heterodimer or TGF-beta Receptor.
'Phase I/II Clinical Trial' shall mean a controlled study in humans of the safety and efficacy of a Licensed Product for a particular indication or indications in subjects having the disease or condition under investigation.
IPSCIO Record ID: 6674
Norelintm is a therapeutic vaccine designed to stimulate in patients production of antibodies against GnRH, resulting in reduced production of hormones that may cause or contribute to the growth of certain sex-hormone dependent cancers. It has completed a Phase I/II safety and immunogenicity trial in hormone-sensitive prostate cancer suggesting that the approach may be better tolerated than currently available therapies.
Compositions and Treatments for Pneumonia in Animals
Issued U.S. Patent No. 5,849,531 a
Leukotoxin Vaccine Compositions and Uses Thereof
Issued U.S. Patent No. 5,871,750 a
Pasteurella haemolytica Leukotoxin Compositions and Uses Thereof
Issued U.S. Patent No. 5,476,657 a
B. Robins and Associates Patent Series 9001-0016
Enhanced Immunogenicity Using Leukotoxin Chimeras
U.S. Application 08/976,566 a
U.S. Patent 5,708,155 a
U.S. Patent 5,422,110 a
GnRH Leukotoxin Chimeras
U.S. Application 09/383,912 a
U.S. Patent 5,969,126 a
U.S. Patent 5,723,129 a
U.S. Patent 5,837,268 a
U.S. Patent 6,022,960 a